At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 677 enrolled
Drug / intervention
memantine ER +1 moredrug
Likely dose
memantine ER 28mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type
In Brief
A Phase 3 clinical trial evaluating memantine ER and Placebo for Dementia of the Alzheimer's Type. Completed, enrolled 677 participants across 83 sites in 4 countries.
Detailed Summary
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDementia of the Alzheimer's Type
CountriesArgentina, Chile, Mexico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
First PostedMay 2006
Primary CompletionOct 2007
Study CompletionJan 2008
TodayJul 2026
First PostedMay 5, 2006
Enrollment StartJun 1, 2005
Primary CompletionOct 1, 2007
Study CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.2 years ago
Interventions
memantine ERdrug
28mg(7mg capsules) once daily and oral administration for 24 weeks.
Placebodrug
Matching placebo oral administration once daily.